The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 2955-2960

  Holland, Edward J ^a,d   McCarthy, Martin ^b   Holland, Simon ^c  

^a CINCINNATI EYE INSTITUTE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Vancouver General Hospital Eye Care Centre   (Canada)

^d Cincinnati Eye Institute   (United States)

Author keywords

Aqueous humor; Cornea; Gatifloxacin; Levofloxacin

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN;

AQUEOUS HUMOR; ARTICLE; BACTERIAL INFECTION; CHOROID HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; CORNEA TRANSPLANTATION; DRUG PENETRATION; EYE DISEASE; EYE INFECTION; EYE PAIN; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KERATOPLASTY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIAL; STORAGE TEMPERATURE; TISSUE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CORNEA; CORNEAL TRANSPLANTATION; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; OPHTHALMIC SOLUTIONS;

EID: 37749047131     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242728     Document Type: Article

References (20)

1. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002;34(Suppl 1):S4-16
2. Hooper DC. Mode of action of fluoroquinolones. Drugs 1999;58(Suppl 2):6-10
3. Abbott RL, Asbell PA, Sahm DF. Ocular TRUST: a new tool for ophthalmology. Ophthalmology Times 2007 July 1:1-4
4. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in aqueous fluid and corneal tissue after topical ophthalmic administration in human volunteers before penetrating keratoplasty. Invest Ophthalmol Vis Sci 2003;44:E-Abstract 4272
5. Kowalski RP, Yates KA, Romanowski EG, et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 2005;112:1987
6. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000;107:1497-502
7. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999;106:1313-18
8. Yeh DL, Stinnett SS, Afshari NA. Analysis of bacterial cultures in infectious keratitis, 1997 to 2004. Am J Ophthalmol 2006;142:1066-8
9. Callegan MC, Ramirez R, Kane ST, et al. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther 2003;20:246-52
10. NDA 21-199, Microbiology Review. Washington, DC: FDA/Center for Drug Evaluation and Research, 2000. Available at: http://www.fda.gov/cder/foi/nda/ 2000/21-199_quixin_microbr.pdf [Last accessed 4 September 2007]
11. Fiscella RG, Nguyen TK, Cwik MJ, et al. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999;106:2286-90
12. Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, et al. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. Journal of cataract and refractive surgery 2001;27:1969-74
13. Pea F, Ferrari E, Pavan F, et al. Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery. Antimicrob Agents Chemo 2005;49:2554-7
14. Puustjarvi T, Terasvirta M, Nurmenniemi P, et al. Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. Graefes Arch Clin Exp Ophthalmol 2006;244:1633-7
15. Sakamoto H, Sakamoto M, Hata Y, et al. Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 2007;17:372-6
16. Kim DH, Stark WJ, O'Brien TP, et al. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005;112:1992-6
17. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112:466-9
18. Fukuda M, Inoue A, Sasaki K, et al. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. Jpn J Ophthalmol 2004;48:93-6
19. Donnenfeld ED, Schrier A, Perry HD, et al. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology 1994;101:902-5
20. Behrens-Baumann W. Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye. Ophthalmologica 1996;210:119-22